Genetic markers and biomarkers for age-related macular degeneration

References

• de Jong PT. Age-related macular degeneration. N. Engl. J. Med.355, 1474–1485 (2006).
   PubMed Web of Science ®Google Scholar
• Gohdes DM, Balamurugan A, Larsen BA, Maylahn C. Age-related eye diseases: an emerging challenge for public health professionals. Prev. Chronic Dis.2, A17 (2005).
   PubMedGoogle Scholar
• Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. Ophthalmology113, 1974–1986 (2006).
   PubMed Web of Science ®Google Scholar
• Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol.6, 125–143 (1999).
   PubMedGoogle Scholar
• Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age-related macular degeneration: a review of progress to date. Surv. Ophthalmol.51, 316–363 (2006).
   PubMed Web of Science ®Google Scholar
• Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science308, 421–424 (2005).
   PubMed Web of Science ®Google Scholar
• Haines JL, Hauser MA, Schmidt S et al. Complement factor H variant increases the risk of age-related macular degeneration. Science308, 419–421 (2005).
   PubMed Web of Science ®Google Scholar
• Klein RJ, Zeiss C, Chew EY et al. Complement Factor H Polymorphism in Age-Related Macular Degeneration. Science308, 385–389 (2005).
   PubMed Web of Science ®Google Scholar
• Conley YP, Thalamuthu A, Jakobsdottir J et al. Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy. Hum. Mol. Genet.14, 1991–2002 (2005).
   PubMed Web of Science ®Google Scholar
• Hageman GS, Anderson DH, Johnson LV et al. From the cover: a common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl Acad. Sci. USA102, 7227–7232 (2005).
   PubMed Web of Science ®Google Scholar
• Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am. J. Hum. Genet.77, 389–407 (2005).
   PubMed Web of Science ®Google Scholar
• Magnusson KP, Duan S, Sigurdsson H et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med.3, E5 (2006).
   PubMed Web of Science ®Google Scholar
• Zareparsi S, Branham KEH, Li M et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am. J. Hum. Genet.77, 149–153 (2005).
   PubMed Web of Science ®Google Scholar
• Conley YP, Jakobsdottir J, Mah T et al.CFH, ELOVL4, PLEKHA1, and LOC387715 genes and susceptibility to age-related maculopathy: AREDS and CHS cohorts and meta-analyses. Hum. Mol. Genet.15, 3206–3218 (2006).
   PubMed Web of Science ®Google Scholar
• Rivera A, Fisher SA, Fritsche LG et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum. Mol. Genet.14, 3227–3236 (2005).
   PubMed Web of Science ®Google Scholar
• Kaur I, Hussain A, Hussain N et al. Analysis of CFH, TLR4, and APOE polymorphism in India suggests the Tyr402His variant of CFH to be a global marker for age-related macular degeneration. Invest. Ophthalmol. Vis. Sci.47, 3729–3735 (2006).
   PubMed Web of Science ®Google Scholar
• Souied EH, Leveziel N, Richard F et al. Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. Mol. Vis.11, 1135–1140 (2005).
   PubMed Web of Science ®Google Scholar
• Despriet DDG, Klaver CCW, Witteman JCM et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA296, 301–309 (2006).
   PubMed Web of Science ®Google Scholar
• Lau LI, Chen SJ, Cheng CY et al. Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients. Invest. Ophthalmol. Vis. Sci.47, 3242–3246 (2006).
   PubMed Web of Science ®Google Scholar
• Sepp T, Khan JC, Thurlby DA et al; the Genetic Factors in AMD Study Group. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest. Ophthalmol. Vis. Sci.47, 536–540 (2006).
   PubMed Web of Science ®Google Scholar
• Fisher SA, Rivera A, Fritsche LG, Babadjanova G, Petrov S, Weber BHF. Assessment of the contribution of CFH and chromosome 10q26 AMD susceptibility loci in a Russian population isolate. Br. J. Ophthalmol.91(5), 576–578 (2006).
   PubMedGoogle Scholar
• Baird PN, Islam FMA, Richardson AJ, Cain M, Hunt N, Guymer R. Analysis of the Y402H variant of the complement factor H gene in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci.47, 4194–4198 (2006).
   PubMed Web of Science ®Google Scholar
• Gotoh N, Yamada R, Hiratani H et al. No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese. Hum. Genet.120, 139–143 (2006).
   PubMed Web of Science ®Google Scholar
• Li M, Atmaca-Sonmez P, Othman M et al. CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat. Genet.38, 1049–1054 (2006).
   PubMed Web of Science ®Google Scholar
• Maller J, George S, Purcell S et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat. Genet.38, 1055–1059 (2006).
   PubMed Web of Science ®Google Scholar
• Muller-Eberhard HJ. Molecular organization and function of the complement system. Ann. Rev. Biochem.57, 321–347 (1988).
   PubMed Web of Science ®Google Scholar
• Gold B, Merriam JE, Zernant J et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet.38, 458–462 (2006).
   PubMed Web of Science ®Google Scholar
• Haines JL, Schnetz-Boutaud N, Schmidt S et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest. Ophthalmol. Vis. Sci.47, 329–335 (2006).
   PubMed Web of Science ®Google Scholar
• Schmidt S, Hauser MA, Scott WK et al. Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am. J. Hum. Genet.78, 852–864 (2006).
   PubMed Web of Science ®Google Scholar
• Ross RJ, Bojanowski CM, Wang JJ et al. The LOC387715 polymorphism and age-related macular degeneration: replication in three case–control samples. Invest. Ophthalmol. Vis. Sci.48, 1128–1132 (2007).
   Google Scholar
• Yang Z, Camp NJ, Sun H et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science314, 992–993 (2006).
   PubMed Web of Science ®Google Scholar
• DeWan A, Liu M, Hartman S et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science314, 989–992 (2006).
   PubMed Web of Science ®Google Scholar
• Ly DH, Lockhart DJ, Lerner RA, Schultz PG. Mitotic misregulation and human aging. Science287, 2486–2492 (2000).
   PubMed Web of Science ®Google Scholar
• Baldi A, De LA, Morini M et al. The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene21, 6684–6688 (2002).
   PubMed Web of Science ®Google Scholar
• Shridhar V, Sen A, Chien J et al. Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res.62, 262–270 (2002).
   PubMedGoogle Scholar
• Hu SI, Carozza M, Klein M, Nantermet P, Luk D, Crowl RM. Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J. Biol. Chem.273, 34406–34412 (1998).
   PubMedGoogle Scholar
• Bakay M, Zhao P, Chen J, Hoffman EP. A web-accessible complete transcriptome of normal human and DMD muscle. Neuromuscul. Disord.12, S125–S141 (2002).
   Google Scholar
• Oka C, Tsujimoto R, Kajikawa M et al. HtrA1 serine protease inhibits signaling mediated by TGF-β family proteins. Development131, 1041–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Tanimoto S, Tamura H, Ue T et al. A polymorphism of LOC387715 gene is associated with age-related macular degeneration in the Japanese population. Neurosci. Lett.414, 71–74 (2007).
   PubMed Web of Science ®Google Scholar
• Tuo J, Ning B, Bojanowski CM et al. Synergic effect of polymorphisms in ERCC6 5´ flanking region and complement factor H on age-related macular degeneration predisposition Proc. Natl Assoc. Sci. USA103, 9256–9261 (2006).
   PubMed Web of Science ®Google Scholar
• Tuo J, Chen C, Zeng X, Christiansen M, Bohr VA. Functional crosstalk between hOgg1 and the helicase domain of Cockayne syndrome group B protein. DNA Repair (Amst.)1, 913–927 (2002).
   PubMed Web of Science ®Google Scholar
• Rinne M, Caldwell D, Kelley MR. Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells. Mol. Cancer Ther.3, 955–967 (2004).
   PubMedGoogle Scholar
• Rosenfeld PJ, Brown DM, Heier JS et al. the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med.355, 1419–1431 (2006).
   PubMed Web of Science ®Google Scholar
• Churchill AJ, Carter JG, Lovell HC et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum. Mol. Genet.15, 2955–2961 (2006).
   PubMed Web of Science ®Google Scholar
• Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res.20, 705–732 (2001).
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol.47, C19–C31 (2006).
   Google Scholar
• Schaumberg DA, Christen WG, Kozlowski P, Miller DT, Ridker PM, Zee RY. A prospective assessment of the Y402H variant in complement factor H, genetic variants in C-reactive protein, and risk of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci.47, 2336–2340 (2006).
   PubMed Web of Science ®Google Scholar
• Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA291, 704–710 (2004).
   PubMed Web of Science ®Google Scholar
• Vine AK, Stader J, Branham K, Musch DC, Swaroop A. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology112, 2076–2080 (2005).
   PubMed Web of Science ®Google Scholar
• Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch. Ophthalmol.123, 774–782 (2005).
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Knudtson MD, Wong TY, Shankar A, Tsai MY. Systemic markers of inflammation, endothelial dysfunction, and age-related maculopathy. Am. J. Ophthalmol.140, 35–44 (2005).
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Marino EK et al. Early age-related maculopathy in the cardiovascular health study. Ophthalmology110, 25–33 (2003).
   PubMed Web of Science ®Google Scholar
• Dasch B, Fuhs A, Behrens T et al. Inflammatory markers in age-related maculopathy: cross-sectional analysis from the Muenster Aging and Retina Study. Arch. Ophthalmol.123, 1501–1506 (2005).
   PubMedGoogle Scholar
• McGwin G, Hall TA, Xie A, Owsley C. The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study. Br. J. Ophthalmol.89, 1166–1170 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV. Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc. Natl Acad. Sci.103, 17456–17461 (2006).
   PubMed Web of Science ®Google Scholar
• Lip PL, Blann AD, Hope-Ross M, Gibson JM, Lip GY. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology108, 705–710 (2001).
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation107, 363–369 (2003).
   PubMed Web of Science ®Google Scholar
• Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch. Ophthalmol.116, 583–587 (1998).
   PubMed Web of Science ®Google Scholar
• Tsai DC, Charng MJ, Lee FL, Hsu WM, Chen SJ. Different plasma levels of vascular endothelial growth factor and nitric oxide between patients with choroidal and retinal neovascularization. Ophthalmologica220, 246–251 (2006).
   PubMed Web of Science ®Google Scholar
• Neuringer M, Anderson GJ, Connor WE. The essentiality of n-3 fatty acids for the development and function of the retina and brain. Annu. Rev. Nutr.8, 517–541 (1988).
   PubMed Web of Science ®Google Scholar
• Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr.83, S1505–S1519 (2006).
   PubMed Web of Science ®Google Scholar
• Seddon JM, Rosner B, Sperduto RD et al. Dietary fat and risk for advanced age-related macular degeneration. Arch. Ophthalmol.119, 1191–1199 (2001).
   PubMed Web of Science ®Google Scholar
• Chua B, Flood V, Rochtchina E, Wang JJ, Smith W, Mitchell P. Dietary fatty acids and the 5-year incidence of age-related maculopathy. Arch. Ophthalmol.124, 981–986 (2006).
   PubMedGoogle Scholar
• Heuberger RA, Mares-Perlman JA, Klein R, Klein BE, Millen AE, Palta M. Relationship of dietary fat to age-related maculopathy in the Third National Health and Nutrition Examination Survey. Arch. Ophthalmol.119, 1833–1838 (2001).
   PubMedGoogle Scholar
• Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US twin study of age-related macular degeneration. Arch. Ophthalmol.124, 995–1001 (2006).
   PubMed Web of Science ®Google Scholar
• Tinoco J, Miljanich P, Medwadowski B. Depletion of docosahexaenoic acid in retinal lipids of rats fed a linolenic acid-deficient, linoleic acid-containing diet. Biochim. Biophys. Acta486, 575–578 (1977).
   PubMedGoogle Scholar
• Anderson GJ, Neuringer M, Lin DS, Connor WE. Can prenatal N-3 fatty acid deficiency be completely reversed after birth? Effects on retinal and brain biochemistry and visual function in rhesus monkeys. Pediatr. Res.58, 865–872 (2005).
   PubMed Web of Science ®Google Scholar
• Hodge WG, Barnes D, Schachter HM et al. The evidence for efficacy of omega-3 fatty acids in preventing or slowing the progression of retinitis pigmentosa: a systematic review. Can. J. Ophthalmol.41, 481–490 (2006).
   PubMed Web of Science ®Google Scholar
• Alvarez RA, Liou GI, Fong SL, Bridges CD. Levels of α- and γ-tocopherol in human eyes: evaluation of the possible role of IRBP in intraocular α-tocopherol transport. Am. J. Clin. Nutr.46, 481–487 (1987).
   PubMed Web of Science ®Google Scholar
• Friedrichson T, Kalbach HL, Buck P, van Kuijk FJ. Vitamin E in macular and peripheral tissues of the human eye. Curr. Eye Res.14, 693–701 (1995).
   PubMed Web of Science ®Google Scholar
• Princen HM, van Duyvenvoorde W, Buytenhek R et al. Supplementation with low doses of vitamin E protects LDL from lipid peroxidation in men and women. Arterioscler. Thromb. Vasc. Biol.15, 325–333 (1995).
   PubMed Web of Science ®Google Scholar
• Lu L, Hackett SF, Mincey A, Lai H, Campochiaro PA. Effects of different types of oxidative stress in RPE cells. J. Cell Physiol.206, 119–125 (2006).
   PubMed Web of Science ®Google Scholar
• Delcourt C, Cristol JP, Tessier F, Leger CL, Descomps B, Papoz L. Age-related macular degeneration and antioxidant status in the POLA study. Arch. Ophthalmol.117, 1384–1390 (1999).
   PubMed Web of Science ®Google Scholar
• Taylor HR, Tikellis G, Robman LD, McCarty CA, McNeil JJ. Vitamin E supplementation and macular degeneration: randomised controlled trial. Br. Med. J.325, 11–15 (2002).
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, β carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol.119, 1417–1436 (2001).
   PubMed Web of Science ®Google Scholar
• Bone RA, Landrum JT. Distribution of macular pigment components, zeaxanthin and lutein, in human retina. Methods Enzymol.213, 360–366 (1992).
   PubMedGoogle Scholar
• Landrum JT, Bone RA. Lutein, zeaxanthin, and the macular pigment. Arch. Biochem. Biophys.385, 28–40 (2001).
   PubMed Web of Science ®Google Scholar
• Nilsson SE, Sundelin SP, Wihlmark U, Brunk UT. Aging of cultured retinal pigment epithelial cells: oxidative reactions, lipofuscin formation and blue light damage. Doc. Ophthalmol.106, 13–16 (2003).
   PubMed Web of Science ®Google Scholar
• Whitehead AJ, Mares JA, Danis RP. Macular pigment: a review of current knowledge. Arch. Ophthalmol.124, 1038–1045 (2006).
   PubMed Web of Science ®Google Scholar
• Bernstein PS, Zhao DY, Wintch SW, Ermakov IV, McClane RW, Gellermann W. Resonance Raman measurement of macular carotenoids in normal subjects and in age-related macular degeneration patients. Ophthalmology109, 1780–1787 (2002).
   PubMed Web of Science ®Google Scholar
• Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, Twaroska EE. Macular pigment in donor eyes with and without AMD: a case–control study. Invest. Ophthalmol. Vis. Sci.42, 235–240 (2001).
   PubMed Web of Science ®Google Scholar
• Koh HH, Murray IJ, Nolan D, Carden D, Feather J, Beatty S. Plasma and macular responses to lutein supplement in subjects with and without age-related maculopathy: a pilot study. Exp. Eye Res.79, 21–27 (2004).
   PubMed Web of Science ®Google Scholar
• Leung IY, Sandstrom MM, Zucker CL, Neuringer M, Snodderly DM. Nutritional manipulation of primate retinas, II. Effects of age, n-3 fatty acids, lutein, and zeaxanthin on retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci.45, 3244–3256 (2004).
   PubMed Web of Science ®Google Scholar
• The Eye Disease Case–Control Study Group. Antioxidant status and neovascular age-related macular degeneration. Arch. Ophthalmol.111, 104–109 (1993).
   PubMed Web of Science ®Google Scholar
• Gale CR, Hall NF, Phillips DI, Martyn CN. Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci.44, 2461–2465 (2003).
   PubMed Web of Science ®Google Scholar
• Delcourt C, Carriere I, Delage M, Barberger-Gateau P, Schalch W. Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study. Invest. Ophthalmol. Vis. Sci.47, 2329–2335 (2006).
   PubMed Web of Science ®Google Scholar
• Mares-Perlman JA, Fisher AI, Klein R et al. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the Third National Health And Nutrition Examination Survey. Am. J. Epidemiol.153, 424–432 (2001).
   PubMed Web of Science ®Google Scholar
• Moeller SM, Parekh N, Tinker L et al. Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women’s Health Initiative. Arch. Ophthalmol.124, 1151–1162 (2006).
   PubMed Web of Science ®Google Scholar
• Upchurch GR Jr, Welch GN, Fabian AJ et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J. Biol. Chem.272, 17012–17017 (1997).
   PubMed Web of Science ®Google Scholar
• Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc. Natl Acad. Sci.89, 10193–10197 (1992).
   PubMed Web of Science ®Google Scholar
• Axer-Siegel R, Bourla D, Ehrlich R et al. Association of neovascular age-related macular degeneration and hyperhomocysteinemia. Am. J. Ophthalmol.137, 84–89 (2004).
   PubMed Web of Science ®Google Scholar
• Seddon JM, Gensler G, Klein ML, Milton RC. Evaluation of plasma homocysteine and risk of age-related macular degeneration. Am. J. Ophthalmol.141, 201–203 (2006).
   PubMed Web of Science ®Google Scholar
• Kamburoglu G, Gumus K, Kadayifcilar S, Eldem B. Plasma homocysteine, vitamin B12 and folate levels in age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol.244, 565–569 (2006).
   PubMed Web of Science ®Google Scholar
• Coral K, Raman R, Rathi S et al. Plasma homocysteine and total thiol content in patients with exudative age-related macular degeneration. Eye20, 203–207 (2006).
   PubMed Web of Science ®Google Scholar
• xer-Siegel R, Bourla D, Ehrlich R et al. Association of neovascular age-related macular degeneration and hyperhomocysteinemia. Am. J. Ophthalmol.137, 84–89 (2004).
   PubMedGoogle Scholar
• Heuberger RA, Fisher AI, Jacques PF et al. Relation of blood homocysteine and its nutritional determinants to age-related maculopathy in the third National Health and Nutrition Examination Survey. Am. J. Clin. Nutr.76, 897–902 (2002).
   PubMed Web of Science ®Google Scholar
• Blann AD, Lip GY. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul. Fibrinolysis9, 297–306 (1998).
   PubMed Web of Science ®Google Scholar
• Malukiewicz-Wisniewska G, Rosc D, Kaluzny B, Kaluzny JJ. von Willebrand factor in plasma of patients with age related macular degeneration. Klin. Oczna107, 70–72 (2005).
   PubMedGoogle Scholar
• Evereklioglu C, Doganay S, Er H, Cekmen M, Ozerol E, Otlu B. Serum leptin concentrations are decreased and correlated with disease severity in age-related macular degeneration: a preliminary study. Eye17, 350–355 (2003).
   PubMedGoogle Scholar
• Okamoto H, Umeda S, Obazawa M et al. Complement factor H polymorphisms in Japanese population with age-related macular degeneration. Mol. Vis.12, 156–158 (2006).
   PubMed Web of Science ®Google Scholar